Address
1 Bartholomew Close
London, EC1A 7BL
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7206 2650
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
October 28, 2003
| Name | Title | Pay | Year Born |
| Timothy Paul McCarthy FCCA | Chairman & Chief Executive Officer | 294,000 | 1956 |
| Sébastien R. Goudreau | Chief Scientific Officer & Director | 3,000 | 1981 |
| Lisa Baderoon | Head of Investor Relations & Non Executive Director | 132,000 | 1966 |
| Timothy Gary Franklin | Chief Operating Officer & Director | 252,000 | 1964 |
| Ashley Louise Clarke | Chief Financial Officer, Company Secretary & Director | 0 | N/A |
| Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs | 0 | N/A |
| Jean-Marie Geiger | Head of Clinical Development | 0 | N/A |
| Laura Mauran-Ambrosino | Head of Research & Development | 0 | N/A |
ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, as well as anti-infective applications. Leading its pipeline is Lupuzor, an autophagy immunomodulator, which is presently undergoing Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disease. Beyond its lead candidate, ImmuPharma is advancing BioAMB, a peptide-based drug designed for Amphotericin-B formulations used against fungal infections caused by the aspergillus family. Another product in development is BioCin, a peptide-based antibacterial agent intended for situations of high medical need and as a last-line defense. The company maintains a collaborative relationship with the Centre National de la Recherche Scientifique to develop a peptide technology platform targeting diabetes through glucagon-like peptide -1 agonists and glucagon antagonists for both type I and type II diabetes. ImmuPharma also holds a license and development agreement with Avion Pharmaceuticals LLC. Founded in 1999, ImmuPharma plc is headquartered in London, United Kingdom.